The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001).
 
Thomas Powles
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Evan Y. Yu
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Exelixis; Janssen; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Matthew T Campbell
Honoraria - Astellas Pharma; AstraZeneca; Axdev; Curio Science; Exelixis; Seagen
Consulting or Advisory Role - EMD Serono; Exelixis; Pfizer; Seagen
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AVEO; Seagen
Other Relationship - Curio Science
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); Loxo/Lilly; MSD Oncology; MSD Oncology (Inst); Pfizer/EMD Serono; Roche; Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Maria De Santis
Honoraria - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Basilea; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; Exelixis/Ipsen; Ferring; Gilead Sciences; Immunomedics; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; MSD Oncology; Novartis; Orion; Pfizer; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen
Consulting or Advisory Role - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Basilea; Bayer; BioClin Therapeutics; BioSyn Healthy Pharma; Bristol-Myers Squibb; Ferring; Gilead Sciences; GlaxoSmithKline; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen; Takeda
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Roche; Roche/Genentech; Sanofi
 
Peter H. O'Donnell
Honoraria - Astellas Pharma; Axiom Healthcare Strategies; CLD, Inc.; Curio Science; EMD Serono; FirstWord; Great Debates and Updates; Institute for Enquiring Minds; IntrinsiQ; ISMIE; MedLearning Group; Merck; MJH Life Sciences; NAMCP; Peerview; Pfizer; Research to Practice; Seagen; Vaniam Group
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Seagen (Inst)
Expert Testimony - Oregon Health & Science University (OHSU)
Travel, Accommodations, Expenses - Curio Science
Other Relationship - Dragonfly Therapeutics; G1 Therapeutics; Janssen; Nektar; NIH
 
Earle F Burgess
Stock and Other Ownership Interests - Arvinas; Becton Dickinson; Calithera Biosciences; Exelixis; Gilead Sciences; Macrogenics; Medtronic
Honoraria - Exelixis; Janssen Oncology; Merck; Novartis; Pfizer
Consulting or Advisory Role - Johnson & Johnson
Speakers' Bureau - AstraZeneca; Exelixis
Research Funding - Astellas Pharma; Pfizer
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Catalym; Clovis Oncology; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences; Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Pfizer; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Laurence E. M. Krieger
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; Ipsen; Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA; Novartis; Pfizer; Roche; Sanofi
Speakers' Bureau - Abbvie; Janssen; Janssen-Cilag; Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA; Roche
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte; Janssen Oncology; Nektar; Taiho Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen
 
Wei Zhang
Employment - Seagen
 
Mari Ichimaru
Employment - Seagen
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792